Technology transfer / Localization · MENA · Announced 20 May 2026

Biocare Biotech → Dorcas Laboratoires

Algeria's Biocare Biotech and Tunisia's Dorcas Laboratoires signed a strategic MoU in Algiers covering technology transfer and export of insulins made full-process in Algeria.

Parties: Biocare Biotech (Groupe Biocare) (Algeria) → Dorcas Laboratoires (Tunisia)

Value
Undisclosed
Territory
Algeria (production base) and Tunisia (partner market), with a stated aim of Maghreb integration
Therapeutic area
Metabolic / Diabetes
Asset
Insulins
Announced
20 May 2026

Our analysis

Why this matters

On 20 May 2026 in Algiers, Groupe BIOCARE, through its subsidiary Biocare Biotech, signed a strategic memorandum of understanding (protocole d'accord) with Tunisia's DORCAS Laboratoires. The agreement covers technology transfer and the export of insulins manufactured full-process in Algeria, with Tunisia as the partner market and a stated aim of Maghreb integration. No financial terms or timelines were published.

The deal fits Algeria's push to turn local insulin production into exports, after years of import substitution.

The full analysis is free to read with a work email on this page.

Source: Esseha

Latest deals

All MENA deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →